# A Study of Outcomes in Chinese Patients Treated With Anifrolumab Who Have Active Mod-severe Systemic Lupus Erythematosus

> **NCT07751848** · PHASE3 · RECRUITING · sponsor: **AstraZeneca** · enrollment: 417 (estimated)

## Conditions studied

- Lupus Erythematosus, Systemic

## Interventions

- **DRUG:** Anifrolumab

## Key facts

- **NCT ID:** NCT07751848
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-08-31
- **Primary completion:** 2028-08-25
- **Final completion:** 2028-08-30
- **Target enrollment:** 417 (ESTIMATED)
- **Last updated:** 2026-09-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07751848

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07751848, "A Study of Outcomes in Chinese Patients Treated With Anifrolumab Who Have Active Mod-severe Systemic Lupus Erythematosus". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07751848. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*